FDA Determines Regulatory Review Period for FACTIVE Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for FACTIVE, a human drug product, as required by law, following the submission of patent extension applications to the Director of Patents and Trademarks at the Department of Commerce.